Early clinical data shows retatrutide produces weight loss exceeding both semaglutide and tirzepatide in head-to-head comparisons
FDA-Approved Brand-Name Medications vs
10.1016/j.cmet.2014.04.005 116 StoffersD
Clinical eligibility for GLP-1 drugs was determined using BMI and the following comorbidities as specified in NHIS: coronary heart disease, prior stroke, prior heart attack, angina, high blood pressure, and high cholesterol
GLP-1 medications still provide major benefits for many patients, including improved blood sugar control and meaningful weight loss
Gastrointestinal function : During treatment, these medications slow gastric emptying, which contributes to prolonged satiety